Key clinical point: Patients with early rheumatoid arthritis (RA) treated with baricitinib monotherapy or baricitinib plus methotrexate vs. methotrexate monotherapy (MM) experienced significantly greater and more rapid pain relief along with more weeks of limited to no pain.

Major finding: Patients treated with baricitinib monotherapy or baricitinib+methotrexate vs. MM reported a significant improvement in pain as early as 2 weeks with sustained improvements and an additional 9-10 weeks of pain-free life over the 52-week treatment period (all P < .001).

Study details: This was a post hoc analysis of the phase 3 study, RA-BEGIN including 588 patients with early RA randomly assigned to receive MM, baricitinib monotherapy, or baricitinib+methotrexate for 52 weeks.

Disclosures: This work was sponsored by Eli Lilly and Company under license from Incyte Corporation. Five authors declared being employees or shareholders of Eli Lilly and Company, and some others declared receiving research grants, consultation fees, honoraria, or speaking fees from various sources, including Eli Lilly and Company.

Source: Taylor PC et al. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 2022;8:e001994 (Mar 9). Doi: 10.1136/rmdopen-2021-001994

Key clinical point: Patients with early rheumatoid arthritis (RA) treated with baricitinib monotherapy or baricitinib plus methotrexate vs. methotrexate monotherapy (MM) experienced significantly greater and more rapid pain relief along with more weeks of limited to no pain.

Major finding: Patients treated with baricitinib monotherapy or baricitinib+methotrexate vs. MM reported a significant improvement in pain as early as 2 weeks with sustained improvements and an additional 9-10 weeks of pain-free life over the 52-week treatment period (all P < .001).

Study details: This was a post hoc analysis of the phase 3 study, RA-BEGIN including 588 patients with early RA randomly assigned to receive MM, baricitinib monotherapy, or baricitinib+methotrexate for 52 weeks.

Disclosures: This work was sponsored by Eli Lilly and Company under license from Incyte Corporation. Five authors declared being employees or shareholders of Eli Lilly and Company, and some others declared receiving research grants, consultation fees, honoraria, or speaking fees from various sources, including Eli Lilly and Company.

Source: Taylor PC et al. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 2022;8:e001994 (Mar 9). Doi: 10.1136/rmdopen-2021-001994

Key clinical point: Patients with early rheumatoid arthritis (RA) treated with baricitinib monotherapy or baricitinib plus methotrexate vs. methotrexate monotherapy (MM) experienced significantly greater and more rapid pain relief along with more weeks of limited to no pain.

Major finding: Patients treated with baricitinib monotherapy or baricitinib+methotrexate vs. MM reported a significant improvement in pain as early as 2 weeks with sustained improvements and an additional 9-10 weeks of pain-free life over the 52-week treatment period (all P < .001).

Study details: This was a post hoc analysis of the phase 3 study, RA-BEGIN including 588 patients with early RA randomly assigned to receive MM, baricitinib monotherapy, or baricitinib+methotrexate for 52 weeks.

Disclosures: This work was sponsored by Eli Lilly and Company under license from Incyte Corporation. Five authors declared being employees or shareholders of Eli Lilly and Company, and some others declared receiving research grants, consultation fees, honoraria, or speaking fees from various sources, including Eli Lilly and Company.

Source: Taylor PC et al. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 2022;8:e001994 (Mar 9). Doi: 10.1136/rmdopen-2021-001994

Key clinical point: Irrespective of human leukocyte antigen-B27 (HLA-B27) status, patients with axial psoriatic arthritis (PsA) experienced mild improvement in disease outcomes after 6 months of initiating targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) or biologic DMARDs (bDMARD).

Major finding: After 6 months, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score remained >4, indicating moderate-to-severe disease activity irrespective of HLA-B27 status, with a mean reduction in BASDAI score of 0.80 and 0.84 (both not clinically meaningful) in the HLA-B27-positive and HLA-B27-negative groups, respectively.

Study details: This prospective, observational study included 135 patients with moderate-to-severe axial PsA who initiated bDMARDs or tsDMARDs and were followed up for 6 months, of which 39 and 96 patients had HLA-B27-positive and HLA-B27-negative status, respectively.

Disclosures: This study was sponsored by CorEvitas, LLC. The authors declared receiving research support, consulting fees, or speaker bureau support from several sources. Two authors declared being employees and shareholders of Johnson and Johnson; three authors declared being present or former employees of CorEvitas, LLC.

Source: Mease PJ et al. treatment responses in patients with psoriatic arthritis axial disease according to human leukocyte antigen-B27 Status: An analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis registry. ACR Open Rheumatol. 2022 (Feb 26). Doi: 10.1002/acr2.11416

Key clinical point: Irrespective of human leukocyte antigen-B27 (HLA-B27) status, patients with axial psoriatic arthritis (PsA) experienced mild improvement in disease outcomes after 6 months of initiating targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) or biologic DMARDs (bDMARD).

Major finding: After 6 months, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score remained >4, indicating moderate-to-severe disease activity irrespective of HLA-B27 status, with a mean reduction in BASDAI score of 0.80 and 0.84 (both not clinically meaningful) in the HLA-B27-positive and HLA-B27-negative groups, respectively.

Study details: This prospective, observational study included 135 patients with moderate-to-severe axial PsA who initiated bDMARDs or tsDMARDs and were followed up for 6 months, of which 39 and 96 patients had HLA-B27-positive and HLA-B27-negative status, respectively.

Disclosures: This study was sponsored by CorEvitas, LLC. The authors declared receiving research support, consulting fees, or speaker bureau support from several sources. Two authors declared being employees and shareholders of Johnson and Johnson; three authors declared being present or former employees of CorEvitas, LLC.

Source: Mease PJ et al. treatment responses in patients with psoriatic arthritis axial disease according to human leukocyte antigen-B27 Status: An analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis registry. ACR Open Rheumatol. 2022 (Feb 26). Doi: 10.1002/acr2.11416

Key clinical point: Irrespective of human leukocyte antigen-B27 (HLA-B27) status, patients with axial psoriatic arthritis (PsA) experienced mild improvement in disease outcomes after 6 months of initiating targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) or biologic DMARDs (bDMARD).

Major finding: After 6 months, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score remained >4, indicating moderate-to-severe disease activity irrespective of HLA-B27 status, with a mean reduction in BASDAI score of 0.80 and 0.84 (both not clinically meaningful) in the HLA-B27-positive and HLA-B27-negative groups, respectively.

Study details: This prospective, observational study included 135 patients with moderate-to-severe axial PsA who initiated bDMARDs or tsDMARDs and were followed up for 6 months, of which 39 and 96 patients had HLA-B27-positive and HLA-B27-negative status, respectively.

Disclosures: This study was sponsored by CorEvitas, LLC. The authors declared receiving research support, consulting fees, or speaker bureau support from several sources. Two authors declared being employees and shareholders of Johnson and Johnson; three authors declared being present or former employees of CorEvitas, LLC.

Source: Mease PJ et al. treatment responses in patients with psoriatic arthritis axial disease according to human leukocyte antigen-B27 Status: An analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis registry. ACR Open Rheumatol. 2022 (Feb 26). Doi: 10.1002/acr2.11416

Key clinical point: Patients with psoriatic arthritis (PsA) reported musculoskeletal pain as the most burdensome symptom and preferred a treatment regimen that improved their joint symptoms and did not include a methotrexate coprescription.

Major finding: Joint pain (98%), fatigue (94%), and morning stiffness (94%) were the most common symptoms of PsA; therefore, 74% of patients preferred therapies that improved joint-related vs. psoriasis-related symptoms, with once-daily oral medication being preferred by 38% of patients and 47% of patients with experience receiving methotrexate preferring a treatment regimen without methotrexate.

Study details: This cross-sectional, web-based survey included 332 adults from ArthritisPower who had a self-reported physician diagnosis of PsA.

Disclosures: This study was funded by AbbVie and RTI Health Solutions. Three authors declared being employees of RTI Health Solutions, two authors declared being employees or share/stockowners of AbbVie, and other authors declared financial/nonfinancial ties with various sources.

Source: Ogdie A et al. Experiences and treatment preferences in patients with psoriatic arthritis: A cross-sectional study in the ArthritisPower registry. Rheumatol Ther. 2022 (Mar 13). Doi: 10.1007/s40744-022-00436-x

Key clinical point: Patients with psoriatic arthritis (PsA) reported musculoskeletal pain as the most burdensome symptom and preferred a treatment regimen that improved their joint symptoms and did not include a methotrexate coprescription.

Major finding: Joint pain (98%), fatigue (94%), and morning stiffness (94%) were the most common symptoms of PsA; therefore, 74% of patients preferred therapies that improved joint-related vs. psoriasis-related symptoms, with once-daily oral medication being preferred by 38% of patients and 47% of patients with experience receiving methotrexate preferring a treatment regimen without methotrexate.

Study details: This cross-sectional, web-based survey included 332 adults from ArthritisPower who had a self-reported physician diagnosis of PsA.

Disclosures: This study was funded by AbbVie and RTI Health Solutions. Three authors declared being employees of RTI Health Solutions, two authors declared being employees or share/stockowners of AbbVie, and other authors declared financial/nonfinancial ties with various sources.

Source: Ogdie A et al. Experiences and treatment preferences in patients with psoriatic arthritis: A cross-sectional study in the ArthritisPower registry. Rheumatol Ther. 2022 (Mar 13). Doi: 10.1007/s40744-022-00436-x

Key clinical point: Patients with psoriatic arthritis (PsA) reported musculoskeletal pain as the most burdensome symptom and preferred a treatment regimen that improved their joint symptoms and did not include a methotrexate coprescription.

Major finding: Joint pain (98%), fatigue (94%), and morning stiffness (94%) were the most common symptoms of PsA; therefore, 74% of patients preferred therapies that improved joint-related vs. psoriasis-related symptoms, with once-daily oral medication being preferred by 38% of patients and 47% of patients with experience receiving methotrexate preferring a treatment regimen without methotrexate.

Study details: This cross-sectional, web-based survey included 332 adults from ArthritisPower who had a self-reported physician diagnosis of PsA.

Disclosures: This study was funded by AbbVie and RTI Health Solutions. Three authors declared being employees of RTI Health Solutions, two authors declared being employees or share/stockowners of AbbVie, and other authors declared financial/nonfinancial ties with various sources.

Source: Ogdie A et al. Experiences and treatment preferences in patients with psoriatic arthritis: A cross-sectional study in the ArthritisPower registry. Rheumatol Ther. 2022 (Mar 13). Doi: 10.1007/s40744-022-00436-x

Key clinical point: In the real-world setting, secukinumab has a satisfactory retention rate in psoriatic arthritis (PsA). However, retention rates are lower in PsA than in psoriasis, with arthritis and obesity being significant predictors of shorter drug survival.

Major finding: Retention rate of secukinumab was higher in psoriasis vs. PsA at 12 (85% vs. 68%) and 24 (61% vs. 57%) months, with the risk for secukinumab discontinuation being higher among patients with arthritis in the overall cohort (hazard ratio 2.43; P = .035) and in patients with obesity in the PsA cohort (P = .021).

Study details: Findings are from a real-life study including 62 patients with psoriasis and 90 patients with PsA who initiated treatment with secukinumab and were followed up for 24 months or until discontinuation.

Disclosures: This study did not receive any funding. R Ramonda and S Piaserico declared receiving honoraria and speaker fees form Novartis, Abbvie, Pfizer, MSD, and Janssen.

Source: Ortolan A et al. Secukinumab drug survival in psoriasis and psoriatic arthritis patients: A 24-month real-life study. Dermatology. 2022 (Mar 9). Doi: 10.1159/000522008

Key clinical point: In the real-world setting, secukinumab has a satisfactory retention rate in psoriatic arthritis (PsA). However, retention rates are lower in PsA than in psoriasis, with arthritis and obesity being significant predictors of shorter drug survival.

Major finding: Retention rate of secukinumab was higher in psoriasis vs. PsA at 12 (85% vs. 68%) and 24 (61% vs. 57%) months, with the risk for secukinumab discontinuation being higher among patients with arthritis in the overall cohort (hazard ratio 2.43; P = .035) and in patients with obesity in the PsA cohort (P = .021).

Study details: Findings are from a real-life study including 62 patients with psoriasis and 90 patients with PsA who initiated treatment with secukinumab and were followed up for 24 months or until discontinuation.

Disclosures: This study did not receive any funding. R Ramonda and S Piaserico declared receiving honoraria and speaker fees form Novartis, Abbvie, Pfizer, MSD, and Janssen.

Source: Ortolan A et al. Secukinumab drug survival in psoriasis and psoriatic arthritis patients: A 24-month real-life study. Dermatology. 2022 (Mar 9). Doi: 10.1159/000522008

Key clinical point: In the real-world setting, secukinumab has a satisfactory retention rate in psoriatic arthritis (PsA). However, retention rates are lower in PsA than in psoriasis, with arthritis and obesity being significant predictors of shorter drug survival.

Major finding: Retention rate of secukinumab was higher in psoriasis vs. PsA at 12 (85% vs. 68%) and 24 (61% vs. 57%) months, with the risk for secukinumab discontinuation being higher among patients with arthritis in the overall cohort (hazard ratio 2.43; P = .035) and in patients with obesity in the PsA cohort (P = .021).

Study details: Findings are from a real-life study including 62 patients with psoriasis and 90 patients with PsA who initiated treatment with secukinumab and were followed up for 24 months or until discontinuation.

Disclosures: This study did not receive any funding. R Ramonda and S Piaserico declared receiving honoraria and speaker fees form Novartis, Abbvie, Pfizer, MSD, and Janssen.

Source: Ortolan A et al. Secukinumab drug survival in psoriasis and psoriatic arthritis patients: A 24-month real-life study. Dermatology. 2022 (Mar 9). Doi: 10.1159/000522008

Key clinical point: The association between abnormalities in renal function parameters and disease activity may be guided by the degree of disease control in psoriatic arthritis (PsA), with disease relapse having a significant effect on renal function in patients with PsA.

Major finding: Renal dysfunction was experienced by 38.5%-58.3% of patients with PsA within 12 months of treatment initiation. Patients with vs. without disease relapse had significantly higher mean serum creatinine levels (P = .031) at treatment initiation; however, clinical remission or treatment type did not seem to affect renal function parameters.

Study details: This single-center retrospective study included 45 patients with PsA (n = 23) or rheumatoid arthritis (n = 22) who received appropriate medication and underwent renal function evaluation every 3-6 months.

Disclosures: This study was supported by Novartis. The authors declared no conflict of interests.

Source: Atzeni F et al. Frequency of renal function parameter abnormalities in patients with psoriatic arthritis and rheumatoid arthritis: Real-world evidence from clinical practice. J Clin Med. 2022;11(4):1029 (Feb 16). Doi: 10.3390/jcm11041029

Key clinical point: The association between abnormalities in renal function parameters and disease activity may be guided by the degree of disease control in psoriatic arthritis (PsA), with disease relapse having a significant effect on renal function in patients with PsA.

Major finding: Renal dysfunction was experienced by 38.5%-58.3% of patients with PsA within 12 months of treatment initiation. Patients with vs. without disease relapse had significantly higher mean serum creatinine levels (P = .031) at treatment initiation; however, clinical remission or treatment type did not seem to affect renal function parameters.

Study details: This single-center retrospective study included 45 patients with PsA (n = 23) or rheumatoid arthritis (n = 22) who received appropriate medication and underwent renal function evaluation every 3-6 months.

Disclosures: This study was supported by Novartis. The authors declared no conflict of interests.

Source: Atzeni F et al. Frequency of renal function parameter abnormalities in patients with psoriatic arthritis and rheumatoid arthritis: Real-world evidence from clinical practice. J Clin Med. 2022;11(4):1029 (Feb 16). Doi: 10.3390/jcm11041029

Key clinical point: The association between abnormalities in renal function parameters and disease activity may be guided by the degree of disease control in psoriatic arthritis (PsA), with disease relapse having a significant effect on renal function in patients with PsA.

Major finding: Renal dysfunction was experienced by 38.5%-58.3% of patients with PsA within 12 months of treatment initiation. Patients with vs. without disease relapse had significantly higher mean serum creatinine levels (P = .031) at treatment initiation; however, clinical remission or treatment type did not seem to affect renal function parameters.

Study details: This single-center retrospective study included 45 patients with PsA (n = 23) or rheumatoid arthritis (n = 22) who received appropriate medication and underwent renal function evaluation every 3-6 months.

Disclosures: This study was supported by Novartis. The authors declared no conflict of interests.

Source: Atzeni F et al. Frequency of renal function parameter abnormalities in patients with psoriatic arthritis and rheumatoid arthritis: Real-world evidence from clinical practice. J Clin Med. 2022;11(4):1029 (Feb 16). Doi: 10.3390/jcm11041029

Key clinical point: The association between abnormalities in renal function parameters and disease activity may be guided by the degree of disease control in psoriatic arthritis (PsA), with disease relapse having a significant effect on renal function in patients with PsA.

Major finding: Renal dysfunction was experienced by 38.5%-58.3% of patients with PsA within 12 months of treatment initiation. Patients with vs. without disease relapse had significantly higher mean serum creatinine levels (P = .031) at treatment initiation; however, clinical remission or treatment type did not seem to affect renal function parameters.

Study details: This single-center retrospective study included 45 patients with PsA (n = 23) or rheumatoid arthritis (n = 22) who received appropriate medication and underwent renal function evaluation every 3-6 months.

Disclosures: This study was supported by Novartis. The authors declared no conflict of interests.

Source: Atzeni F et al. Frequency of renal function parameter abnormalities in patients with psoriatic arthritis and rheumatoid arthritis: Real-world evidence from clinical practice. J Clin Med. 2022;11(4):1029 (Feb 16). Doi: 10.3390/jcm11041029

Key clinical point: The association between abnormalities in renal function parameters and disease activity may be guided by the degree of disease control in psoriatic arthritis (PsA), with disease relapse having a significant effect on renal function in patients with PsA.

Major finding: Renal dysfunction was experienced by 38.5%-58.3% of patients with PsA within 12 months of treatment initiation. Patients with vs. without disease relapse had significantly higher mean serum creatinine levels (P = .031) at treatment initiation; however, clinical remission or treatment type did not seem to affect renal function parameters.

Study details: This single-center retrospective study included 45 patients with PsA (n = 23) or rheumatoid arthritis (n = 22) who received appropriate medication and underwent renal function evaluation every 3-6 months.

Disclosures: This study was supported by Novartis. The authors declared no conflict of interests.

Source: Atzeni F et al. Frequency of renal function parameter abnormalities in patients with psoriatic arthritis and rheumatoid arthritis: Real-world evidence from clinical practice. J Clin Med. 2022;11(4):1029 (Feb 16). Doi: 10.3390/jcm11041029

Key clinical point: The association between abnormalities in renal function parameters and disease activity may be guided by the degree of disease control in psoriatic arthritis (PsA), with disease relapse having a significant effect on renal function in patients with PsA.

Major finding: Renal dysfunction was experienced by 38.5%-58.3% of patients with PsA within 12 months of treatment initiation. Patients with vs. without disease relapse had significantly higher mean serum creatinine levels (P = .031) at treatment initiation; however, clinical remission or treatment type did not seem to affect renal function parameters.

Study details: This single-center retrospective study included 45 patients with PsA (n = 23) or rheumatoid arthritis (n = 22) who received appropriate medication and underwent renal function evaluation every 3-6 months.

Disclosures: This study was supported by Novartis. The authors declared no conflict of interests.

Source: Atzeni F et al. Frequency of renal function parameter abnormalities in patients with psoriatic arthritis and rheumatoid arthritis: Real-world evidence from clinical practice. J Clin Med. 2022;11(4):1029 (Feb 16). Doi: 10.3390/jcm11041029

Key clinical point: In the initial 16 weeks of this phase 2 trial, patients with psoriatic arthritis (PsA) achieved higher response with deucravacitinib vs. placebo along with a consistent safety profile.

Major finding: At week 16, American College of Rheumatology-20 (ACR20) response was significantly higher with 6 mg once-daily deucravacitinib (adjusted odds ratio [aOR] 2.4; P = .0134) and 12 mg (aOR 3.6; P = .0004) vs. placebo (31.8%), with 12 mg deucravacitinib improving ACR20 response as early as at 8 weeks (P < .05). No serious adverse events were reported in patients treated with deucravacitinib.

Study details: Findings are from a phase 2 study including 203 patients with active PsA intolerant to ≥1 therapy who were randomly assigned to receive 6 mg deucravacitinib once a day, 12 mg deucravacitinib once daily, or placebo for 16 weeks.

Disclosures: This study was sponsored by Bristol Myers Squibb. Eight authors declared being employees or shareholders of Bristol Myers Squibb or of receiving payments or speaker/consultant fees from Bristol Myers Squibb.

Source: Mease PJ et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 (Mar 3). Doi: 10.1136/annrheumdis-2021-221664

Key clinical point: In the initial 16 weeks of this phase 2 trial, patients with psoriatic arthritis (PsA) achieved higher response with deucravacitinib vs. placebo along with a consistent safety profile.

Major finding: At week 16, American College of Rheumatology-20 (ACR20) response was significantly higher with 6 mg once-daily deucravacitinib (adjusted odds ratio [aOR] 2.4; P = .0134) and 12 mg (aOR 3.6; P = .0004) vs. placebo (31.8%), with 12 mg deucravacitinib improving ACR20 response as early as at 8 weeks (P < .05). No serious adverse events were reported in patients treated with deucravacitinib.

Study details: Findings are from a phase 2 study including 203 patients with active PsA intolerant to ≥1 therapy who were randomly assigned to receive 6 mg deucravacitinib once a day, 12 mg deucravacitinib once daily, or placebo for 16 weeks.

Disclosures: This study was sponsored by Bristol Myers Squibb. Eight authors declared being employees or shareholders of Bristol Myers Squibb or of receiving payments or speaker/consultant fees from Bristol Myers Squibb.

Source: Mease PJ et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 (Mar 3). Doi: 10.1136/annrheumdis-2021-221664

Key clinical point: In the initial 16 weeks of this phase 2 trial, patients with psoriatic arthritis (PsA) achieved higher response with deucravacitinib vs. placebo along with a consistent safety profile.

Major finding: At week 16, American College of Rheumatology-20 (ACR20) response was significantly higher with 6 mg once-daily deucravacitinib (adjusted odds ratio [aOR] 2.4; P = .0134) and 12 mg (aOR 3.6; P = .0004) vs. placebo (31.8%), with 12 mg deucravacitinib improving ACR20 response as early as at 8 weeks (P < .05). No serious adverse events were reported in patients treated with deucravacitinib.

Study details: Findings are from a phase 2 study including 203 patients with active PsA intolerant to ≥1 therapy who were randomly assigned to receive 6 mg deucravacitinib once a day, 12 mg deucravacitinib once daily, or placebo for 16 weeks.

Disclosures: This study was sponsored by Bristol Myers Squibb. Eight authors declared being employees or shareholders of Bristol Myers Squibb or of receiving payments or speaker/consultant fees from Bristol Myers Squibb.

Source: Mease PJ et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022 (Mar 3). Doi: 10.1136/annrheumdis-2021-221664

Key clinical point: A magnetic resonance imaging (MRI)-based scoring method was sensitive to changes in clinical outcomes of psoriatic arthritis (PsA) caused by abatacept, validating the responsiveness of the OMERACT PsA MRI Scoring System.

Major finding: Until day 169, patients receiving 30 mg/kg abatacept with a switch over to 10 mg/kg and those receiving 10 mg/kg abatacept reported significant reduction in MRI-detected synovitis (−0.97; P = .04) and tenosynovitis (−1.65; P = .01) vs. placebo, with patients switching from placebo to 10 mg/kg abatacept at day 169 showing significant improvements in total inflammation, synovitis, and tenosynovitis (P < .05) up to day 365.

Study details: This was a post hoc analysis of a phase 2b study including 123 patients with active PsA and an inadequate response to disease-modifying antirheumatic drugs randomly assigned to receive abatacept or placebo.

Disclosures: This study was funded by Bristol Myers Squibb. The authors declared serving on speakers’ bureaus and as consultants or receiving grants/research support from several sources. Six authors declared being employees or shareholders of Bristol Myers Squibb.

Source: Østergaard M et al. Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology (Oxford). 2022 (Feb 8). Doi: 10.1093/rheumatology/keac073

Key clinical point: A magnetic resonance imaging (MRI)-based scoring method was sensitive to changes in clinical outcomes of psoriatic arthritis (PsA) caused by abatacept, validating the responsiveness of the OMERACT PsA MRI Scoring System.

Major finding: Until day 169, patients receiving 30 mg/kg abatacept with a switch over to 10 mg/kg and those receiving 10 mg/kg abatacept reported significant reduction in MRI-detected synovitis (−0.97; P = .04) and tenosynovitis (−1.65; P = .01) vs. placebo, with patients switching from placebo to 10 mg/kg abatacept at day 169 showing significant improvements in total inflammation, synovitis, and tenosynovitis (P < .05) up to day 365.

Study details: This was a post hoc analysis of a phase 2b study including 123 patients with active PsA and an inadequate response to disease-modifying antirheumatic drugs randomly assigned to receive abatacept or placebo.

Disclosures: This study was funded by Bristol Myers Squibb. The authors declared serving on speakers’ bureaus and as consultants or receiving grants/research support from several sources. Six authors declared being employees or shareholders of Bristol Myers Squibb.

Source: Østergaard M et al. Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology (Oxford). 2022 (Feb 8). Doi: 10.1093/rheumatology/keac073

Key clinical point: A magnetic resonance imaging (MRI)-based scoring method was sensitive to changes in clinical outcomes of psoriatic arthritis (PsA) caused by abatacept, validating the responsiveness of the OMERACT PsA MRI Scoring System.

Major finding: Until day 169, patients receiving 30 mg/kg abatacept with a switch over to 10 mg/kg and those receiving 10 mg/kg abatacept reported significant reduction in MRI-detected synovitis (−0.97; P = .04) and tenosynovitis (−1.65; P = .01) vs. placebo, with patients switching from placebo to 10 mg/kg abatacept at day 169 showing significant improvements in total inflammation, synovitis, and tenosynovitis (P < .05) up to day 365.

Study details: This was a post hoc analysis of a phase 2b study including 123 patients with active PsA and an inadequate response to disease-modifying antirheumatic drugs randomly assigned to receive abatacept or placebo.

Disclosures: This study was funded by Bristol Myers Squibb. The authors declared serving on speakers’ bureaus and as consultants or receiving grants/research support from several sources. Six authors declared being employees or shareholders of Bristol Myers Squibb.

Source: Østergaard M et al. Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Rheumatology (Oxford). 2022 (Feb 8). Doi: 10.1093/rheumatology/keac073

Key clinical point: Humoral response to BNT162b2 mRNA SARS-CoV-2 vaccine was reduced in patients with psoriatic arthritis (PsA) who received immunomodulatory treatment with antitumor necrosis factor (TNF) therapy, methotrexate, or interleukin 17 inhibitor compared with those without PsA.

Major finding: The median anti-SARS-CoV-2 spike receptor-binding domain immunoglobulin G (IgG) antibody level after 3 weeks of receiving the second dose of BNT162b2 mRNA SARS-CoV-2 vaccine was significantly higher in individuals without vs. with PsA (1,562.00 vs. 928.00 binding antibody units (BAU)/mL; P ≤ .001). The levels were, however, similar across anti-TNF therapy, secukinumab, or methotrexate treatment groups (P = .73).

Study details: Findings are from a prospective study including 110 patients with PsA in clinical remission who received immunomodulatory treatment and were matched with 96 healthy healthcare workers, all of whom had previously received two shots of the BNT162b2 mRNA SARS-CoV-2 vaccine.

Disclosures: The study did not report any source of funding. The authors declared no conflict of interests.

Source: Benucci M et al. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? Front Med. 2022;9:811829 (Feb 28). Doi: 10.3389/fmed.2022.811829

Key clinical point: Humoral response to BNT162b2 mRNA SARS-CoV-2 vaccine was reduced in patients with psoriatic arthritis (PsA) who received immunomodulatory treatment with antitumor necrosis factor (TNF) therapy, methotrexate, or interleukin 17 inhibitor compared with those without PsA.

Major finding: The median anti-SARS-CoV-2 spike receptor-binding domain immunoglobulin G (IgG) antibody level after 3 weeks of receiving the second dose of BNT162b2 mRNA SARS-CoV-2 vaccine was significantly higher in individuals without vs. with PsA (1,562.00 vs. 928.00 binding antibody units (BAU)/mL; P ≤ .001). The levels were, however, similar across anti-TNF therapy, secukinumab, or methotrexate treatment groups (P = .73).

Study details: Findings are from a prospective study including 110 patients with PsA in clinical remission who received immunomodulatory treatment and were matched with 96 healthy healthcare workers, all of whom had previously received two shots of the BNT162b2 mRNA SARS-CoV-2 vaccine.

Disclosures: The study did not report any source of funding. The authors declared no conflict of interests.

Source: Benucci M et al. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? Front Med. 2022;9:811829 (Feb 28). Doi: 10.3389/fmed.2022.811829

Key clinical point: Humoral response to BNT162b2 mRNA SARS-CoV-2 vaccine was reduced in patients with psoriatic arthritis (PsA) who received immunomodulatory treatment with antitumor necrosis factor (TNF) therapy, methotrexate, or interleukin 17 inhibitor compared with those without PsA.

Major finding: The median anti-SARS-CoV-2 spike receptor-binding domain immunoglobulin G (IgG) antibody level after 3 weeks of receiving the second dose of BNT162b2 mRNA SARS-CoV-2 vaccine was significantly higher in individuals without vs. with PsA (1,562.00 vs. 928.00 binding antibody units (BAU)/mL; P ≤ .001). The levels were, however, similar across anti-TNF therapy, secukinumab, or methotrexate treatment groups (P = .73).

Study details: Findings are from a prospective study including 110 patients with PsA in clinical remission who received immunomodulatory treatment and were matched with 96 healthy healthcare workers, all of whom had previously received two shots of the BNT162b2 mRNA SARS-CoV-2 vaccine.

Disclosures: The study did not report any source of funding. The authors declared no conflict of interests.

Source: Benucci M et al. Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response? Front Med. 2022;9:811829 (Feb 28). Doi: 10.3389/fmed.2022.811829

Key clinical point: Ustekinumab and a tumor necrosis factor inhibitor (TNFi) showed comparable efficacy, safety, and drug persistence after 1 year of treatment in real-world patients with psoriatic arthritis (PsA).

Major finding: After 1 year of treatment, ustekinumab vs. TNFi showed similar persistence (hazard ratio for stopping/switching treatment 0.82; 95% CI 0.60-1.13) and a similar proportion of patients achieving clinical low disease activity  on the Disease Activity Index for PsA  (odds ratio [OR] 0.80; 95% CI 0.57-1.10) and remission (OR 0.73; 95% CI 0.49-1.07), along with a similar safety profile.

Study details: Findings are from a 1-year analysis of the prospective, observational PsABio study including 893 patients with PsA who were prescribed first-line to third-line ustekinumab or TNFis.

Disclosures: PsABio study was sponsored by Janssen. The authors declared receiving grants, personal fees, consulting fees, research support, nonfinancial support, and honoraria from several sources, including Janssen. Three authors declared being employees or shareholders of Janssen or Johnson and Johnson, Janssen’s corporate parent.

Source: Gossec L et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022 (Feb 24). Doi: 10.1136/annrheumdis-2021-221640

Key clinical point: Ustekinumab and a tumor necrosis factor inhibitor (TNFi) showed comparable efficacy, safety, and drug persistence after 1 year of treatment in real-world patients with psoriatic arthritis (PsA).

Major finding: After 1 year of treatment, ustekinumab vs. TNFi showed similar persistence (hazard ratio for stopping/switching treatment 0.82; 95% CI 0.60-1.13) and a similar proportion of patients achieving clinical low disease activity  on the Disease Activity Index for PsA  (odds ratio [OR] 0.80; 95% CI 0.57-1.10) and remission (OR 0.73; 95% CI 0.49-1.07), along with a similar safety profile.

Study details: Findings are from a 1-year analysis of the prospective, observational PsABio study including 893 patients with PsA who were prescribed first-line to third-line ustekinumab or TNFis.

Disclosures: PsABio study was sponsored by Janssen. The authors declared receiving grants, personal fees, consulting fees, research support, nonfinancial support, and honoraria from several sources, including Janssen. Three authors declared being employees or shareholders of Janssen or Johnson and Johnson, Janssen’s corporate parent.

Source: Gossec L et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022 (Feb 24). Doi: 10.1136/annrheumdis-2021-221640

Key clinical point: Ustekinumab and a tumor necrosis factor inhibitor (TNFi) showed comparable efficacy, safety, and drug persistence after 1 year of treatment in real-world patients with psoriatic arthritis (PsA).

Major finding: After 1 year of treatment, ustekinumab vs. TNFi showed similar persistence (hazard ratio for stopping/switching treatment 0.82; 95% CI 0.60-1.13) and a similar proportion of patients achieving clinical low disease activity  on the Disease Activity Index for PsA  (odds ratio [OR] 0.80; 95% CI 0.57-1.10) and remission (OR 0.73; 95% CI 0.49-1.07), along with a similar safety profile.

Study details: Findings are from a 1-year analysis of the prospective, observational PsABio study including 893 patients with PsA who were prescribed first-line to third-line ustekinumab or TNFis.

Disclosures: PsABio study was sponsored by Janssen. The authors declared receiving grants, personal fees, consulting fees, research support, nonfinancial support, and honoraria from several sources, including Janssen. Three authors declared being employees or shareholders of Janssen or Johnson and Johnson, Janssen’s corporate parent.

Source: Gossec L et al. Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study. Ann Rheum Dis. 2022 (Feb 24). Doi: 10.1136/annrheumdis-2021-221640